MAP2K7 and glioma: Moreover, decrease of contrast enhancement during chemotherapy, treatment with bevacizumab or mitogen-activated protein kinase kinase (MEK) inhibitors is well known, but is not necessarily evidence of response [27], which might be the reason why it is no longer included as response criteria in clinical trials for pediatric glioma [20, 28].